JP2013509435A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509435A5
JP2013509435A5 JP2012537131A JP2012537131A JP2013509435A5 JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5 JP 2012537131 A JP2012537131 A JP 2012537131A JP 2012537131 A JP2012537131 A JP 2012537131A JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5
Authority
JP
Japan
Prior art keywords
patient
injectable
depot
dose
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054807 external-priority patent/WO2011053829A1/en
Publication of JP2013509435A publication Critical patent/JP2013509435A/ja
Publication of JP2013509435A5 publication Critical patent/JP2013509435A5/ja
Pending legal-status Critical Current

Links

JP2012537131A 2009-10-30 2010-10-29 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン Pending JP2013509435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
US61/256,696 2009-10-30
PCT/US2010/054807 WO2011053829A1 (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015237117A Division JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Publications (2)

Publication Number Publication Date
JP2013509435A JP2013509435A (ja) 2013-03-14
JP2013509435A5 true JP2013509435A5 (https=) 2013-12-19

Family

ID=43302985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537131A Pending JP2013509435A (ja) 2009-10-30 2010-10-29 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン
JP2015237117A Pending JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015237117A Pending JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Country Status (12)

Country Link
US (2) US20110105536A1 (https=)
EP (1) EP2493473A1 (https=)
JP (2) JP2013509435A (https=)
KR (1) KR20120116401A (https=)
CN (1) CN102802631A (https=)
AU (2) AU2010313290A1 (https=)
BR (1) BR112012010195A2 (https=)
CA (1) CA2742393A1 (https=)
CL (1) CL2012001110A1 (https=)
MX (1) MX2012005083A (https=)
NZ (1) NZ599558A (https=)
WO (1) WO2011053829A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
AU2013235526B2 (en) * 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
AU2016244801B2 (en) * 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2020356529A1 (en) 2019-09-25 2022-05-19 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
WO2022049006A1 (en) * 2020-09-02 2022-03-10 Janssen Pharmaceutica Nv Pre-filled syringe with optimized stopper placement
IL303253A (en) * 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release injectable formulations of paliperidone
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
MX2023006368A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
EP4308077A1 (en) * 2021-03-17 2024-01-24 MedinCell S.A. Long acting injectable formulation comprising risperidone and biodegradable polymers
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
US20080177067A1 (en) * 2006-08-14 2008-07-24 Ben-Zion Dolitzky Crystal forms of 9-hydroxy-risperidone (paliperidone)
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação

Similar Documents

Publication Publication Date Title
JP2013509435A5 (https=)
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
JP2015187125A5 (https=)
JP2014114288A5 (https=)
JP2017031213A5 (https=)
JP2015512392A5 (https=)
JP2018510894A5 (https=)
JP2011511072A5 (https=)
JP2019196370A5 (https=)
JP2016514132A5 (https=)
IL273976B1 (en) Methods and materials for nt-3 gene therapy
SI2523688T1 (en) Formulation of antibodies and therapeutic regimes
JP2017538705A5 (https=)
JP2013543501A5 (https=)
FI3998078T3 (fi) Annoksensuurentamisentsyymikorvaushoito happaman sfingomyelinaasin puutoksen hoitamista varten
JP2010531879A5 (https=)
JP2012193216A5 (https=)
FI4119569T3 (fi) Konjugoituja antisense-yhdisteitä käytettäviksi hoidossa
JP2018531605A5 (https=)
JP2019511506A5 (https=)
RU2019107146A (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
Gopalakrishna et al. Long-acting injectable aripiprazole: how might it fit in our tool box?
Remington et al. 2012 CCNP Innovations Award Paper: Antipsychotic dosing: found in translation
JP2016515137A5 (https=)